02601nas a2200469   4500000000100000008004100001260001700042653001500059653001000074653001300084653002500097653002400122653001500146653001700161653001100178653001100189653001500200653001100215653002900226653001100255653001000266653002500276653000900301653001400310653002600324653001600350653002900366653001300395100001500408700001300423700001700436700001600453700001800469700001400487700001300501700001400514245013500528300001000663490000700673520143700680022001402117       2007                            d  c2007 Nov-Dec10aAdolescent10aAdult10aAmylases10aAntiprotozoal Agents10aBlood Urea Nitrogen10aCreatinine10aElectrolytes10aFemale10aHumans10aInjections10aKidney10aLeishmaniasis, Cutaneous10aLipase10aLiver10aLiver Function Tests10aMale10aMeglumine10aMeglumine Antimoniate10aMiddle Aged10aOrganometallic Compounds10aPancreas1 aKashani MN1 aFirooz A1 aEskandari SE1 aGhoorchi MH1 aKhamesipour A1 aKhatami A1 aJavadi A1 aDowlati Y00aEvaluation of meglumine antimoniate effects on liver, kidney and pancreas function tests in patients with cutaneous leishmaniasis.  a513-50 v173 a<p>Cutaneous leishmaniasis has been recognized as a major public health problem in several countries. Pentavalent antimonies, meglumine antimoniate and sodium stibogluconate, have been considered as standard treatment for leishmaniasis. Side effects have been reported to be increased hepatic enzyme levels and electrocardiographic abnormalities. We performed this study to evaluate the influence of meglumine antimoniate on some liver, kidney, and pancreas function tests. Eighty patients fulfilled the study criteria. Forty-one (51.3%) patients were female and the mean age of the patients was 30.4 +/- 15.7 years. Blood samples were taken to evaluate liver, kidney, and pancreas function tests before and after treatment with intramuscular injections of MA at a dose of 20 mg Sb(+5)/kg/day for 15 days. Mean serum levels of blood urea nitrogen, creatinine, sodium, total and direct bilirubin, aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase significantly increased after treatment, although most of them were within normal ranges. There were no significant differences in serum levels of potassium, amylase, lipase, and gamma-glutamyl transpeptidase before and after treatment. In conclusion it can be stated that one course of treatment with 20 mg Sb(+5)/kg/day MA for 15 days does not significantly alter the liver, kidney and pancreas function tests in patients with cutaneous Leishmaniasis.</p>  a1167-1122